Analyst Price Target is $97.50
▲ +17.22% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Haemonetics in the last 3 months. The average price target is $97.50, with a high forecast of $110.00 and a low forecast of $84.00. The average price target represents a 17.22% upside from the last price of $83.18.
Current Consensus is
The current consensus among 6 investment analysts is to buy stock in Haemonetics. This Buy consensus rating has held steady for over two years.
Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.